Plain-English translation of NCT04090034 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is studying a treatment called peptide receptor radionuclide therapy (PRRT), which uses a radioactive substance to target and treat neuroendocrine tumors—rare cancers that grow slowly in the digestive system. Researchers are collecting information about how well the medication works, how long patients survive, and what side effects people experience when they receive this treatment.
Many patients with neuroendocrine tumors develop advanced disease that cannot be removed with surgery, and they need effective systemic treatments to slow or stop cancer growth. This study exists to better understand how this medication performs in real patients and to gather more information that can help doctors decide when and how to use it.
You likely qualify if…
You likely don't qualify if…
If you qualify, your doctor will give you the radioactive peptide injection as part of your standard cancer treatment plan. The study team will collect information about your medical history, how your tumor responds to the treatment (measured by imaging scans), how long you survive, and any side effects or complications you experience. You will need to be able to follow the study requirements and attend follow-up visits so researchers can monitor your progress.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
United States
Sponsor
Methodist Health System
Enrollment target
~50 participants
Started
March 2024
Primary completion
June 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in March 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Colette N Ndjom, MS
Liver Institute at Methodist Dallas Medical Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.